{"created":"2023-07-27T06:56:42.198954+00:00","id":53602,"links":{},"metadata":{"_buckets":{"deposit":"d3d567b7-26aa-4732-b637-256f2cbdeabe"},"_deposit":{"created_by":18,"id":"53602","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"53602"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00053602","sets":["2812:2813:2821"]},"author_link":["69438","95236"],"item_9_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2013-05-09","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"4p.","bibliographicVolumeNumber":"2011 – 2012","bibliographic_titles":[{"bibliographic_title":"平成24(2012)年度 科学研究費補助金 若手研究(B) 研究成果報告書"},{"bibliographic_title":"2012 Fiscal Year Final Research Report","bibliographic_titleLang":"en"}]}]},"item_9_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{}],"nameIdentifiers":[{},{}]}]},"item_9_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"EGFRに結合し、PI3K/PDK1/Aktの活性化を橋渡しする新規足場蛋白であるAki1に着目し、その制御がEGFR変異を有する肺癌における新しい治療標的になりうるかについて研究した。複数のEGFR変異を有する肺癌細胞株でAki1が高発現していることを確認し、siRNA法にてAki1阻害を行ったところ、細胞増殖抑制およびアポトーシス増加を示した。EGFR変異を有する肺癌細胞株をマウスに皮下移植し作成した動物モデルではsiRNA法を用いたAki1遺伝子発現抑制により著明な抗腫瘍効果を示した。さらに、EGFR変異を有する肺癌腫瘍ではEGFR阻害薬治療の有無に関わらず、高頻度にAki1高発現を認めた。これらの研究成果により、Aki1はEGFR阻害薬の耐性EGFR-T790M変異を含めたEGFR変異を有する非小細胞肺癌の新たな標的分子である可能性がある。","subitem_description_type":"Abstract"},{"subitem_description":"We focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K /PDK1/Akt, and assessed its role in EGFR mutant lung cancer. Aki1 constitutively associates with mutant EGFR in lung cancer cells. Silencing of Aki1 inhibited cell growth of EGFR mutant lung cancer cells and induced apoptosis of them. Treatment with Aki1 siRNA dramatically inhibited growth of EGFR mutant lung cancer cells in a xenograft model. Moreover, Aki1 was frequently expressed in tumor cells of EGFR mutant lung cancer patients, including those with acquired resistance to EGFR-TKI treatment. Our data suggest that Aki1 may be an ideal target for EGFR mutant lung cancer patients, especially those with acquired EGFR-TKI resistance due to EGFR T790M gatekeeper mutation.","subitem_description_type":"Abstract"}]},"item_9_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号:23790902, 研究期間(年度):2011-2012","subitem_description_type":"Other"},{"subitem_description":"出典：研究課題「新規足場蛋白Aki1を標的としたEGFR遺伝子変異肺癌の制御法開発」課題番号23790902\n（KAKEN：科学研究費助成事業データベース（国立情報学研究所））\n（https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23790902/23790902seika/）を加工して作成","subitem_description_type":"Other"}]},"item_9_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学附属病院","subitem_description_type":"Other"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00059884","subitem_identifier_reg_type":"JaLC"}]},"item_9_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/search/?qm=00507048"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/search/?qm=00507048","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23790902/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23790902/","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23790902/23790902seika/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23790902/23790902seika/","subitem_relation_type_select":"URI"}}]},"item_9_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-11-20"}],"displaytype":"detail","filename":"ME-PR-WASEDA-R-kaken 2013-4p.pdf","filesize":[{"value":"386.1 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"ME-PR-WASEDA-R-kaken 2013-4p.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/53602/files/ME-PR-WASEDA-R-kaken 2013-4p.pdf"},"version_id":"fa58976a-e8bb-4909-af2a-16623b6749e9"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"新規足場蛋白Aki1を標的としたEGFR遺伝子変異肺癌の制御法開発","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"新規足場蛋白Aki1を標的としたEGFR遺伝子変異肺癌の制御法開発"},{"subitem_title":"Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations","subitem_title_language":"en"}]},"item_type_id":"9","owner":"18","path":["2821"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-11-20"},"publish_date":"2020-11-20","publish_status":"0","recid":"53602","relation_version_is_last":true,"title":["新規足場蛋白Aki1を標的としたEGFR遺伝子変異肺癌の制御法開発"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2023-07-27T12:08:22.132949+00:00"}